Spatial Memory Impairment Without Apoptosis Induced by the Combination of Beta-Amyloid Oligomers and Cerebral Ischemia Is Related to Decreased Acetylcholine Release in Rats

The purpose of the present study was to examine the effect of beta-amyloid (Aβ ) oligomers, not the fibrils that make up Aβ plaques, on spatial memory and the cholinergic system in rats. Recently, several researchers have suggested that small assemblies of Aβ, Aβ oligomers, caused memory loss during...

Full description

Bibliographic Details
Main Authors: Takuya Watanabe, Katsunori Iwasaki, Shin Ishikane, Tetsuya Naitou, Yoshitaka Yoshimitsu, Norito Yamagata, Mehmeto Bülent Ozdemir, Kotaro Takasaki, Nobuaki Egashira, Kenichi Mishima, Michihiro Fujiwara
Format: Article
Language:English
Published: Elsevier 2008-01-01
Series:Journal of Pharmacological Sciences
Online Access:http://www.sciencedirect.com/science/article/pii/S1347861319315397
Description
Summary:The purpose of the present study was to examine the effect of beta-amyloid (Aβ ) oligomers, not the fibrils that make up Aβ plaques, on spatial memory and the cholinergic system in rats. Recently, several researchers have suggested that small assemblies of Aβ, Aβ oligomers, caused memory loss during the early stages of Alzheimer’s disease without showing cell death. In the present study, the combination of Aβ oligomers and cerebral ischemia, but not cerebral ischemia alone, significantly impaired spatial memory without apoptosis in the CA1 region of the hippocampus. Donepezil, an acetylcholinesterase inhibitor, ameliorated this memory impairment. Therefore we examined acetylcholine (ACh) release from the dorsal hippocampus. A microdialysis study showed that spontaneous release of ACh was not significantly decreased by the combination of Aβ oligomers and cerebral ischemia; however, high K+-evoked ACh release was decreased. These results suggest that a combination of Aβ oligomers and cerebral ischemia induces memory impairment by cholinergic synapse dysfunction without apoptosis. This model may be useful for developing new drugs for the treatment of early-phase Alzheimer’s disease. Keywords:: Alzheimer’s disease, oligomer, acetylcholine, memory impairment, behavior
ISSN:1347-8613